Cargando…

Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein

Dimethyl sulfoxide (DMSO) is a highly utilized small molecule that serves many purposes in scientific research. DMSO offers unique polar, aprotic and amphiphilic features, which makes it an ideal solvent for a wide variety of both polar and nonpolar molecules. Furthermore, DMSO is often used as a cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Reimer, Lasse, Haikal, Caroline, Gram, Hjalte, Theologidis, Vasileios, Kovacs, Gergo, Ruesink, Harm, Baun, Andreas, Nielsen, Janni, Otzen, Daniel Erik, Li, Jia-Yi, Jensen, Poul Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904838/
https://www.ncbi.nlm.nih.gov/pubmed/35260646
http://dx.doi.org/10.1038/s41598-022-07706-2
_version_ 1784665034878615552
author Reimer, Lasse
Haikal, Caroline
Gram, Hjalte
Theologidis, Vasileios
Kovacs, Gergo
Ruesink, Harm
Baun, Andreas
Nielsen, Janni
Otzen, Daniel Erik
Li, Jia-Yi
Jensen, Poul Henning
author_facet Reimer, Lasse
Haikal, Caroline
Gram, Hjalte
Theologidis, Vasileios
Kovacs, Gergo
Ruesink, Harm
Baun, Andreas
Nielsen, Janni
Otzen, Daniel Erik
Li, Jia-Yi
Jensen, Poul Henning
author_sort Reimer, Lasse
collection PubMed
description Dimethyl sulfoxide (DMSO) is a highly utilized small molecule that serves many purposes in scientific research. DMSO offers unique polar, aprotic and amphiphilic features, which makes it an ideal solvent for a wide variety of both polar and nonpolar molecules. Furthermore, DMSO is often used as a cryoprotectant in cell-based research. However, recent reports suggest that DMSO, even at low concentration, might interfere with important cellular processes, and cause macromolecular changes to proteins where a shift from α-helical to β-sheet structure can be observed. To investigate how DMSO might influence current research, we assessed biochemical and cellular impacts of DMSO treatment on the structure of the aggregation-prone protein α-synuclein, which plays a central role in the etiology of Parkinson’s disease, and other brain-related disorders, collectively termed the synucleinopathies. Here, we found that addition of DMSO increased the particle-size of α-synuclein, and accelerated the formation of seeding-potent fibrils in a dose-dependent manner. These fibrils made in the presence of DMSO were indistinguishable from fibrils made in pure PBS, when assessed by proteolytic digestion, cytotoxic profile and their ability to seed cellular aggregation of α-synuclein. Moreover, as evident through binding to the MJFR-14-6-4-2 antibody, which preferentially recognizes aggregated forms of α-synuclein, and a bimolecular fluorescence complementation assay, cells exposed to DMSO experienced increased aggregation of α-synuclein. However, no observable α-synuclein abnormalities nor differences in neuronal survival were detected after oral DMSO-treatment in either C57BL/6- or α-synuclein transgenic F28 mice. In summary, we demonstrate that low concentrations of DMSO makes α-synuclein susceptible to undergo aggregation both in vitro and in cells. This may affect experimental outcomes when studying α-synuclein in the presence of DMSO, and should call for careful consideration when such experiments are planned.
format Online
Article
Text
id pubmed-8904838
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89048382022-03-10 Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein Reimer, Lasse Haikal, Caroline Gram, Hjalte Theologidis, Vasileios Kovacs, Gergo Ruesink, Harm Baun, Andreas Nielsen, Janni Otzen, Daniel Erik Li, Jia-Yi Jensen, Poul Henning Sci Rep Article Dimethyl sulfoxide (DMSO) is a highly utilized small molecule that serves many purposes in scientific research. DMSO offers unique polar, aprotic and amphiphilic features, which makes it an ideal solvent for a wide variety of both polar and nonpolar molecules. Furthermore, DMSO is often used as a cryoprotectant in cell-based research. However, recent reports suggest that DMSO, even at low concentration, might interfere with important cellular processes, and cause macromolecular changes to proteins where a shift from α-helical to β-sheet structure can be observed. To investigate how DMSO might influence current research, we assessed biochemical and cellular impacts of DMSO treatment on the structure of the aggregation-prone protein α-synuclein, which plays a central role in the etiology of Parkinson’s disease, and other brain-related disorders, collectively termed the synucleinopathies. Here, we found that addition of DMSO increased the particle-size of α-synuclein, and accelerated the formation of seeding-potent fibrils in a dose-dependent manner. These fibrils made in the presence of DMSO were indistinguishable from fibrils made in pure PBS, when assessed by proteolytic digestion, cytotoxic profile and their ability to seed cellular aggregation of α-synuclein. Moreover, as evident through binding to the MJFR-14-6-4-2 antibody, which preferentially recognizes aggregated forms of α-synuclein, and a bimolecular fluorescence complementation assay, cells exposed to DMSO experienced increased aggregation of α-synuclein. However, no observable α-synuclein abnormalities nor differences in neuronal survival were detected after oral DMSO-treatment in either C57BL/6- or α-synuclein transgenic F28 mice. In summary, we demonstrate that low concentrations of DMSO makes α-synuclein susceptible to undergo aggregation both in vitro and in cells. This may affect experimental outcomes when studying α-synuclein in the presence of DMSO, and should call for careful consideration when such experiments are planned. Nature Publishing Group UK 2022-03-08 /pmc/articles/PMC8904838/ /pubmed/35260646 http://dx.doi.org/10.1038/s41598-022-07706-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Reimer, Lasse
Haikal, Caroline
Gram, Hjalte
Theologidis, Vasileios
Kovacs, Gergo
Ruesink, Harm
Baun, Andreas
Nielsen, Janni
Otzen, Daniel Erik
Li, Jia-Yi
Jensen, Poul Henning
Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
title Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
title_full Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
title_fullStr Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
title_full_unstemmed Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
title_short Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein
title_sort low dose dmso treatment induces oligomerization and accelerates aggregation of α-synuclein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904838/
https://www.ncbi.nlm.nih.gov/pubmed/35260646
http://dx.doi.org/10.1038/s41598-022-07706-2
work_keys_str_mv AT reimerlasse lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT haikalcaroline lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT gramhjalte lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT theologidisvasileios lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT kovacsgergo lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT ruesinkharm lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT baunandreas lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT nielsenjanni lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT otzendanielerik lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT lijiayi lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein
AT jensenpoulhenning lowdosedmsotreatmentinducesoligomerizationandacceleratesaggregationofasynuclein